Virus Peptides TRIZ Cases

Directed-evolution AAV capsid variants improve glioblastoma cell binding, tumor penetration, and gene transduction in glioma.

Targeted mutations in the AAV capsid 561-588 region improve tissue tropism and payload packaging for more efficient gene delivery.

Non-identical capsid half-dimers enable controlled asymmetric virus-like particle assembly, cargo loading, and addressable holey capsids.

HDAC inhibitor cell culture boosts rAAV yield two-fold or more, cutting GMP manufacturing cost and improving scale-up.

Engineered AAV capsid substitutions improve skeletal and cardiac muscle transduction while reducing brain and liver uptake and immune risk.

Specific VP1 capsid mutations improve AAV delivery to retinal pigment epithelium while preserving capsid integrity for intravitreal or subretinal use.

Targeted VP1 mutations in AAV capsids shift tropism and improve payload packaging for more precise and efficient gene delivery.

Deleting ICP6 and IR regions creates a replication-competent HSV-1 vector that accepts larger therapeutic genes and selectively kills cancer cells.

Synthetic anellovectors and anelloVLPs deliver therapeutic agents while reducing immune response and minimizing genomic integration.

LMP1-expressing B cells boost antigen presentation and prime broad T cell responses, helping overcome tumor antigen loss and weak checkpoint therapy.

Combining rep-cap and adenovirus helper genes into one plasmid simplifies transfection and boosts rAAV yield while cutting production time and cost.

By inactivating the HERV-K envelope ISD in adenoviral VLP vaccines, this case shows broader CD4/CD8 activation and tumor control.

High-affinity spike-binding antibodies neutralize virus infectivity and extend protection to newly identified coronaviruses.

Separate inducible Rep, Cap, and helper modules let packaging cells tune AAV titer, full capsid ratio, and cell health during production.

A dual-host plasmid strategy uses E. coli and B. subtilis amplification to improve virus-derived construct yield and vector genome copy number.

Specific AAV capsid residue changes modulate AAVR binding to reduce liver off-target transduction while preserving delivery to target tissues.

Peptide inserts in AAV capsid variable regions improve muscle tropism and specificity while reducing liver targeting in gene therapy.

Clinical HSV isolates are selected and engineered with fusogenic and immune-stimulatory genes to kill tumors faster and boost antitumor immunity.

Transient p53 inhibition boosts HDR in gene-edited hematopoietic stem cells, improving survival, engraftment, and editing efficiency.

Surface-exposed peptide inserts in rAAV capsids improve targeting to muscle, CNS, and retina while reducing liver transduction and dosing.

CMV Triplex vaccination expands dual-specific CAR T cells in vivo to improve persistence, engraftment, and anti-tumor activity after HCT.

Knocking out C1s protease in CHO cells prevents gp120 cleavage, raising yields of full-length HIV envelope proteins for vaccine production.

Modified VP1, VP2, and VP3 capsids limit deamidation during storage, helping AAV vectors retain purity, stability, and transduction efficiency.

Targeted capsid mutations shift AAV9 delivery toward cardiac cells while lowering liver transduction, dose burden, and inflammation.

Selective CRBN-binding compounds preserve target protein degradation while avoiding ASS1 recruitment, ubiquitination, and side effects.

Capsid-only anellovectors deliver therapeutic genetic cargo to eukaryotic cells while reducing immune response and minimizing genomic integration.

Combining adenoviral, HSV, and HBoV helper functions in one plasmid boosts infectious rAAV yield across serotypes and cell lines.

Differential codon bias in separate Rep52 and Rep78 sequences limits recombination in baculoviral insect-cell AAV production and improves yield stability.

Cell-type-specific promoters enable RNA-driven AAV capsid screening for targeted CNS transduction without transgenic animals.

Peptide insertions in rAAV capsids improve brain, spinal cord, and heart transduction while reducing off-target liver expression.

Engineered hybrid AAV capsids combine serotype sequences to improve cell transduction while reducing neutralization by human antibodies.

A sulfamoylbenzamide linker tag loads proteins inside or outside HBV VLPs at high density without disrupting capsid assembly.

Targeted amino acid changes in AAV capsids improve liver targeting, boost gene expression, and help evade neutralizing antibodies.

Mature dendritic cells loaded with HIV and herpesvirus peptides reverse HIV latency and activate CD8+ T cells without global immune activation.

Modified AAVrh.91 capsids use deamidated VP proteins to bypass preexisting immunity and improve gene delivery to CNS, heart, and muscle.

Deamidated AAVrh.90 capsids help rAAV vectors evade preexisting immunity and improve transduction across CNS and peripheral tissues.

Targeted AAV capsid mutations improve CNS infectivity while reducing liver tropism, toxicity, and repeat-dosing barriers in gene therapy.

Targeted capsid motif changes boost heart transduction while reducing liver trafficking, lowering dose-related inflammation risk.

Local rAAV delivery on hydroxyapatite silences SOST and SHN3 to boost WNT-driven bone formation and speed fracture union with fewer side effects.

Specific AAV2 capsid substitutions improve blood-brain barrier crossing and deep brain transduction for sustained CNS gene expression.

Balancing long and short AAV rep expression with heterologous elements boosts full capsids, lowers cytotoxicity, and improves rAAV potency.

Separating cap genes while adding accessory proteins to the rep plasmid boosts rAAV titer, potency, and transduction efficiency.

Targeted VP1, VP2, and VP3 substitutions raise AAVR affinity to improve transduction efficiency and lower dose-driven immunogenicity.

Multimodal anion exchange ligands combine hydrophobic and anionic binding to separate full AAV capsids from empty ones at scalable recovery and purity.

Fluorescent SDS capillary electrophoresis separates viral from non-specific proteins to improve titer accuracy and purity assessment.

High-affinity human antibodies target the coronavirus spike protein to block infectivity and improve survival in infected animal models.

Direct plasma isolation and chromatographic separation define circulating HIV-neutralizing antibodies and deliver broad pseudovirus coverage.

Separate Rep52 and Rep78 sequences with differential codon bias reduce baculoviral recombination and sustain high-yield rAAV production.

Specific VP1 capsid substitutions improve AAV2 delivery to retinal and RPE tissues while preserving vector stability for intravitreal and subretinal use.

CMV antigen re-stimulation expands dual-specific CAR T cells in vivo, improving persistence, engraftment, and anti-tumor activity.

Surface-exposed capsid sequence changes improve rAAV delivery to synovial tissue and fibroblast-like synoviocytes while lowering neutralizing antibodies.

TRACER platform recovers specific AAV capsid mRNA variants to overcome low transduction efficiency in adult central nervous system applications.